ASCIA HAE Position Paper and Management Plan

The management of hereditary angioedema (HAE) is evolving, with more options for long-term prophylaxis that are now available. The ASCIA HAE position paper and management plan have been updated to include new treatments and to be consistent with international guidelines.

The most recent updates in 2022 have been made on pages 9, 10, 16. 20 and 27.

HAE references are available at www.allergy.org.au/hp/papers/hereditary-angioedema-references

Updated ASCIA HAE Position Paper 2022 - Updated October 2022

ASCIA HP Position Paper HAE 20221.13 MB

New ASCIA HAE Management Plan 2022 (with type in fields), which replaces the ASCIA HAE Action Plan.
ASCIA HAE Management Plan 2022103.95 KB

New ASCIA HAE Case Peer Review Form (with type in fields), which needs to be completed when requesting prophylaxis dose increases using a new treatment option - Berinert® SC.
ASCIA HAE Case Peer Review Form 202091.69 KB

Notice from Cipla regarding supply of icatibant

Cipla Icatibant Information109.55 KB

Notice from Takeda regarding delisting of Firazyr (icatibant) from PBS in Australia.

HCP_letter_Firazyr_PBS_Update_002726.08 KB

For information regarding supply of danazol in Australia please refer to www.allergy.org.au/about-ascia/info-updates/product-supply-update-danazol

ASCIA HAE Working Party members are listed at www.allergy.org.au/members/committees#wp

HAE Australasia is a support organisation for people with HAE and their carers in Australia and New Zealand. For more information visit www.haeaustralasia.org.au

For information about how ASCIA information for health professionals is developed go to: www.allergy.org.au/about-ascia/website-information

Content updated November 2022